Avadel Pharmaceuticals
AVDL
#5513
Rank
C$1.47 B
Marketcap
$15.28
Share price
3.71%
Change (1 day)
-17.27%
Change (1 year)

P/E ratio for Avadel Pharmaceuticals (AVDL)

P/E ratio as of December 2024 (TTM): -5.10

According to Avadel Pharmaceuticals 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -5.10096. At the end of 2022 the company had a P/E ratio of -3.13.

P/E ratio history for Avadel Pharmaceuticals from 2001 to 2023

PE ratio at the end of each year

Year P/E ratio Change
2022-3.13-48.92%
2021-6.12-114.66%
202041.8-592.15%
2019-8.48738.45%
2018-1.01-120.11%
20175.03-151.32%
2016-9.80-178.67%
201512.5-279.65%
2014-6.9445.6%
2013-4.76-107.94%
201260.0-514.75%
2011-14.53.47%
2010-14.0-11.16%
2009-15.7100.83%
2008-7.8424.12%
2007-6.32-68.58%
2006-20.127.76%
2005-15.7-148.44%
200432.5-138.8%
2003-83.7-148.35%
2002173-1245.83%
2001-15.1

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
-0.9953-80.49%๐Ÿ‡บ๐Ÿ‡ธ USA
-5.63 10.36%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.